CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
Earnings
CytomX Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 15, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$1.70M
-71.7% on a year earlier
EPS, Q3 FY2026
-$0.09
-$0.09 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of CytomX Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 15, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $1.70M | -71.7% | -$0.09 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $1.40M | -92.5% | -$0.09 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $10.30M | -79.8% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 16, 2026before the open | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $6.00M | -82.0% | -$0.09 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $18.70M | -25.5% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | $50.90M | +22.7% | $0.27 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 6, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $33.40M | +26.5% | $0.07 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $25.10M | +1.6% | -$0.08 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $41.50M | +76.6% | $0.17 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 11, 2024after the close | $26.60M | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $26.40M | +56.2% | $0.04 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $24.70M | +37.2% | -$0.02 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | $23.50M | +37.4% | -$0.05 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 27, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $16.90M | -6.1% | -$0.35 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $18.00M | – | -$0.37 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $17.10M | – | -$0.37 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022after the close | $19.70M | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $18.00M | – | -$0.35 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 19, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
CytomX Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When CytomX Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases CytomX Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Results
See a number that looks wrong?